NCT06781827 Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease
| NCT ID | NCT06781827 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wecare Probiotics Co., Ltd. |
| Condition | Inflammatory Bowel Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2025-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2025-01-01 with a primary completion date of 2025-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This project involves the use of oral Lactobacillus reuteri as an adjunct therapy for 8 weeks. Endoscopic observation of intestinal inflammation will be conducted at 1 month, 3 months, 6 months, and 12 months after the administration of the drug. Intestinal fluid will be collected endoscopically for 16S RNA analysis to assess changes in the gut microbiota. Inflammatory changes in the patients will be detected through peripheral blood tests, and fecal calprotectin levels will be measured to evaluate the progression of the disease.
Eligibility Criteria
Inclusion Criteria: 1. Be over 18 years old 2. Agree to sign informed consent; Have been diagnosed with IBD for at least 3 months but not more than 3 years - Exclusion Criteria: 1. Does not meet the diagnostic criteria of CD 2. Patients with other autoimmune diseases, infectious diseases and malignant tumors Patients with CD during pregnancy and lactation; Patients with serious diseases of the liver, kidney, heart and lung, etc 3. Patients with allergic diseases such as asthma and allergic rhinitis; alcoholic Patients with mental illness 4. Patients with suspected cancer in their intestines 5. Antibiotics, probiotics and prebiotics have been used in the past three months Had intestinal surgery (except appendicitis surgery) 6. There is currently an infection 7. He has had cancer in the last 5 years -
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06781827 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Inflammatory Bowel Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06781827 currently recruiting?
Yes, NCT06781827 is actively recruiting participants. Contact the research team at 775804281@qq.com for enrollment information.
Where is the NCT06781827 trial being conducted?
This trial is being conducted at Suqian, China.
Who is sponsoring the NCT06781827 clinical trial?
NCT06781827 is sponsored by Wecare Probiotics Co., Ltd.. The trial plans to enroll 50 participants.